Navigation Links
Angiotech Expands Quill(TM) SRS product offering receiving FDA 510(k) approval for smaller size diameters of Quill(TM) SRS PDO
Date:5/1/2008

VANCOUVER, May 1 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and medical device company, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to begin marketing sizes 3-0 and 4-0 of its Quill Self-Retaining System (SRS) Polydioxanone (PDO) product line. The Quill SRS PDO is a longer-lasting absorbable suture, which is typically used for deeper tissue closures. These smaller diameter sizes incorporate a new design for better holding strength and expand the number and scope of procedures that can be done with the Quill SRS product.

"We are pleased to receive 510(k) approval for these new smaller diameter sizes. We intend to continue to broaden our Quill SRS product offering to cover multiple procedures for wound closure and tissue approximation," said Dr. William Hunter, President and CEO of Angiotech.

Angiotech plans to exhibit the Quill SRS product line at the Annual Meeting of the American Society for Aesthetic Plastic Surgery (ASAPS) to be held May 1-6 in San Diego, California.

About the Quill(TM) Self-Retaining System (SRS)

The Quill SRS represents a revolutionary technology in wound closure made possible by bidirectional fixation within the wound. Its patented design allows the surgeon to begin closure at the midpoint of the wound and suture in two directions from the midpoint. Barbs within the Quill SRS distribute tension across the wound and eliminate the need for knots. This highly efficient, knot-less system can save significant procedural time in the operating room while also enhancing wound closure.

Note on Forward Looking Statements

Statements contained in this pres
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Angiotech elects to suspend Vascular Wrap(TM) pivotal clinical trials
2. Angiotechs Corporate Partner, Boston Scientific, Reports Canadian Approval for TAXUS(R) Liberte(R) Stent System
3. Angiotechs novel 5-FU Central Venous Catheter receives FDA 510(k) clearance
4. Angiotech announces director resignation
5. Angiotech announces commercial launch of Cook Medicals Zilver(R) PTX(TM) drug-eluting peripheral stent in New Zealand
6. Angiotech to participate in Credit Suisse Global Leveraged Finance Conference
7. 960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotechs Novel 5-FU Central Venous Catheter
8. Angiotech to participate in Lehman Brothers Healthcare Conference
9. Angiotech announces filing of audited financial results for the year ended December 31, 2007 and restatement of results for the year ended December 31, 2006
10. Angiotech and Rex Medical announce exclusive licensing and distribution agreement for the "Option(TM)" inferior vena cava filter
11. Angiotech showcases its Hemostream(TM) Dialysis Catheter at the Society of Interventional Radiology (SIR) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... -- The Board of Directors of BD (Becton, Dickinson and ... dividend of 54.5 cents per common share payable on September ... The indicated annual dividend rate is $2.18 per share. ... medical technology company that partners with customers and stakeholders to ... needs. Our innovative solutions are focused on improving drug delivery, ...
(Date:7/22/2014)... the National Institute of Standards and Technology (NIST) ... a new design for an atomic clock that ... a microcomb. , The microcomb clock, featured on ... new journal Optica ,* is the first ... its accurate conversion of optical frequencies to lower ...
(Date:7/22/2014)... a senior lecturer in mechanical engineering at the University ... the Year by the North Texas section of the ... more than 130,000 members in 158 countries who develop ... assist the engineering community, benefiting the world. , ASME ... of Professional Engineers honors banquet. Baughn retired as an ...
(Date:7/22/2014)... July 22, 2014 Nuclear reactors are ... produced by controlled fission chain reaction in nuclear reactors ... is used to drive a power- generating turbine. Currently ... the world’s total electricity production. Nuclear reactor market is ... construction, planned and proposed nuclear reactor projects. , Early ...
Breaking Biology Technology:'Comb on a chip' powers new NIST/Caltech atomic clock design 2UT Dallas professor receives Engineer of the Year award 2Nuclear Energy Market: Global Industry Analysis, Size, Share, Analysis, Growth and Forecast 2013 - 2019 2Nuclear Energy Market: Global Industry Analysis, Size, Share, Analysis, Growth and Forecast 2013 - 2019 3
... N.C., Jan. 5, 2012 Tengion, Inc. (NASDAQ: ... medicine, today announced it has completed the relocation ... to the Company,s existing facility in Winston-Salem, North ... previously announced restructuring, which was designed to fund ...
... SARASOTA, Fla., Jan. 5, 2012  George Miller developed an ... His doctor sent cell scrapings to a pathologist, and ... TMD Limited, a medical tourism company, squamous cell carcinoma ... humans and other animals.  Squamous cell ...
... Jan. 5, 2012  AtheroNova, (OTCQB: AHRO) ("AtheroNova"), a biotech company ... atherosclerotic plaque, announced today that it has appointed Johan M. ... Directors of the Company effective January 3, 2012. Mr. Spoor ... and Medical Committees of the Board. "I ...
Cached Biology Technology:Tengion Announces Relocation of Corporate Headquarters to Current Facility in Winston-Salem, North Carolina 2Tengion Announces Relocation of Corporate Headquarters to Current Facility in Winston-Salem, North Carolina 3Tengion Announces Relocation of Corporate Headquarters to Current Facility in Winston-Salem, North Carolina 4Squamous Cell Cancer Responds to SPDT Therapy 2Squamous Cell Cancer Responds to SPDT Therapy 3Squamous Cell Cancer Responds to SPDT Therapy 4AtheroNova Announces a New Board Member 2AtheroNova Announces a New Board Member 3
(Date:7/23/2014)... HOLE, MA -- What do mollusks, starfish, and ... marine habitat, they are all calcifiersorganisms that use ... skeletons and shells for stability and protection. , ... , published by the Marine Biological Laboratory, addresses ... composition changes worldwide. , As atmospheric carbon dioxide ...
(Date:7/23/2014)... the principal bacteria that cause dental caries, has ... time, possibly coinciding with dietary change linked to ... in a study by researchers from the Universitat ... de Genmica para la Biodiversidad (National Laboratory of ... first time, have sequenced genetic material from this ...
(Date:7/23/2014)... popular culinary herbs oregano and rosemary are packed with ... work in much the same way as prescription anti-diabetic ... ACS, Journal of Agricultural and Food Chemistry , ... a difference, and they also identified which compounds contribute ... de Mejia and colleagues point out that in 2012, ...
Breaking Biology News(10 mins):Calcification in changing oceans explored in special issue of The Biological Bulletin 2Ancient genetic material from caries bacterium obtained for the first time 2
... total energy used in the USA is taken up in ... comes from non-renewable energy sources which are in short supply. ... reducing this significant fuel consumption in the US food system ... the Springer journal Human Ecology , David Pimentel and ...
... CO, USA GEOLOGY topics include confirmation that ... a blowout in the Banjar Panji-1 well; evidence of the ... analysis of Yellowstone,s hotspot; and GPS measurements that show why ... GSA Today ,s science article studies the impact of Glen ...
... medicines and the introduction of new anti-arthritis drugs ... (RA), according to guidelines issued by the American ... the University of Alabama at Birmingham (UAB). ... in the UAB Division of Clinical Immunology and ...
Cached Biology News:Why eating less can help the environment 2August 2008 Geology and GSA Today media highlights 2August 2008 Geology and GSA Today media highlights 3August 2008 Geology and GSA Today media highlights 4August 2008 Geology and GSA Today media highlights 5August 2008 Geology and GSA Today media highlights 6August 2008 Geology and GSA Today media highlights 7August 2008 Geology and GSA Today media highlights 8August 2008 Geology and GSA Today media highlights 9August 2008 Geology and GSA Today media highlights 10August 2008 Geology and GSA Today media highlights 11August 2008 Geology and GSA Today media highlights 12New guidelines for treating rheumatoid arthritis 2
IRF7 Immunogen: Synthetic peptide corresponding to residues E(463) G T Q R E G V S S L D S S S(477) of human IRF7. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Rabbit polyclonal to NMDAR1 e/f/g/h ( Abpromise for all tested applications)....
Rabbit polyclonal to TetR ( Abpromise for all tested applications). Antigen: Synthetic peptide: AQKLGVEQPTLYWHVKNKR, corresponding to amino acids 31 - 49 of TetR...
Polyclonal Antibody to Coronin / CORO1C This antibody was developed against synthetic peptides corresponding to amino acids 407-420 of human CORO1C....
Biology Products: